Key Highlights
₹200,108 Mn
Total Revenue From Operations
₹39,307 Mn
EBITDA
1,420,000+
Patients Reached Through Patient Education Programs
78,000+
HCPs Participated in Doctor Education Programs
21% YoY
Reduction in Scope 1 and Scope 2 Emissions in FY24
R&D
866
Active Patent Applications up to March 2024
442
ANDAs and NDAs filled with U.S. FDA up to March 2024
Rankings
3rd
in the U.S. (by prescriptions)
7th
in Indian Pharma Market
11th
Largest Generics Company Globally
Products
25+
Robust Pipeline of injectables for FY25
15+
Robust Pipeline of Respiratory Products for FY25
27 Bn+
Formulation Units Sold Globally (IQVIA MAT Mar 24 Standard Units)
Assurance Statement